A Study of HR071603 (Ketamine Nasal Spray) in Healthy Subjects

Randomized, parallel-group Phase I study in healthy male volunteers (n=50) comparing HR071603 (R-ketamine) nasal spray versus placebo with dose-escalation cohorts to evaluate safety and pharmacokinetics.

Primary assessments include adverse events, vital signs, ECG and clinical labs; pharmacokinetic sampling will characterise systemic exposure across dose cohorts.